JPH0770133A - Cyathane derivative and nerve growth factor production inducing agent and antigbacterial agent containing the derivative as active component - Google Patents

Cyathane derivative and nerve growth factor production inducing agent and antigbacterial agent containing the derivative as active component

Info

Publication number
JPH0770133A
JPH0770133A JP5240544A JP24054493A JPH0770133A JP H0770133 A JPH0770133 A JP H0770133A JP 5240544 A JP5240544 A JP 5240544A JP 24054493 A JP24054493 A JP 24054493A JP H0770133 A JPH0770133 A JP H0770133A
Authority
JP
Japan
Prior art keywords
derivative
cyathane
mycelium
organic solvent
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP5240544A
Other languages
Japanese (ja)
Other versions
JP2657894B2 (en
Inventor
Hirokazu Kawagishi
洋和 河岸
Fumihiro Kojima
文博 小嶋
Kenji Okamoto
賢治 岡本
Hideki Sakamoto
秀樹 坂本
Yukio Ishiguro
幸雄 石黒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagome Co Ltd
Original Assignee
Kagome Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagome Co Ltd filed Critical Kagome Co Ltd
Priority to JP5240544A priority Critical patent/JP2657894B2/en
Priority claimed from US08/196,049 external-priority patent/US5391544A/en
Priority to US08/196,049 priority patent/US5391544A/en
Priority to ES94301549T priority patent/ES2104272T3/en
Priority to AT94301549T priority patent/ATE153340T1/en
Priority to DE69403242T priority patent/DE69403242T2/en
Priority to EP94301549A priority patent/EP0613903B1/en
Publication of JPH0770133A publication Critical patent/JPH0770133A/en
Publication of JP2657894B2 publication Critical patent/JP2657894B2/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE:To obtain a new cyathane derivative existing in the cultured mycelium of Hericium erinaceum. CONSTITUTION:The cyathane derivative expressed by the formula and existing in the cultured mycelium of Hericium erinaceum which is a kind of mushroom belonging to the genus Hericium, family Hydnaceae. The cyathane derivative can be produced by culturing mycelium of Hericium erinaceum in medium, separating the obtained cultured mycelium into supernatant and precipitated mycelium by centrifugal separation, extracting the cultured mycelium with homogeneous system consisting of water and an organic solvent, heating the extracted liquid to evaporate the organic solvent to obtain an aqueous phase, subjecting the aqueous phase to liquid-liquid partition extraction with a mixture of water and an organic solvent, collecting the organic solvent layer, evaporating the solvent and fractionating the obtained dry solid by chromatography.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、ハリタケ科( Hydnace
ae )、サンゴハリタケ属( Hericium )のキノコであ
るヤマブシタケ( Hericium erinaceum )の培養菌糸体
中に含まれるシアタン( cyathane )誘導体及びこれを
有効成分とする神経成長因子(NGF)産生誘導剤並び
に抗菌剤に関する。
BACKGROUND OF THE INVENTION The present invention relates to Hydaceae (Hydnaceae).
ae), a cyathane derivative contained in the cultured mycelium of Hericium erinaceum, a mushroom of the genus Hericium, and a nerve growth factor (NGF) production inducer and antibacterial agent containing the same .

【0002】[0002]

【従来の技術】従来、キノコの子実体中に含まれる化合
物及びその薬剤効果については複数の報告がある。例え
ば、サルノコシカケ科のキノコであるカワラタケ( Pol
yporusversicolor )の子実体中にはエルゴステロール
誘導体が含まれており、該エルゴステロール誘導体には
肝臓癌細胞に対する殺細胞効果のあることがテトラヘド
ロン( Tetrahedron )39,2779〜2785(1
983)に報告されている。またハラタケ科のキノコで
あるヒメマツタケ( Agaricus blazei )の子実体中に
もエルゴステロール誘導体が含まれており、該エルゴス
テロール誘導体には子宮頸癌細胞に対する殺細胞効果の
あることがフィトケミストリ( Phytochemistry )2
7,2777〜2789(1988)に報告されてい
る。同様のことは特公昭48−6766号公報、特公昭
55−71702号公報、特公昭58−62118号公
報等にも報告されている。
2. Description of the Related Art Heretofore, there have been a number of reports on compounds contained in mushroom fruiting bodies and their drug effects. For example, the mushrooms of the Sarcobidae family
The fruiting body of yporus versicolor) contains an ergosterol derivative, and the fact that the ergosterol derivative has a cell-killing effect on liver cancer cells is tetrahedron (Tetrahedron) 39, 2779-2785 (1).
983). The fruiting body of Agaricus blazei, which is a mushroom of the agaricid family, also contains an ergosterol derivative, and the ergosterol derivative has a cell-killing effect on cervical cancer cells. Phytochemistry Two
7, 2777-2789 (1988). The same thing is reported in Japanese Patent Publication No. 48-6766, Japanese Patent Publication No. 55-71702, Japanese Patent Publication No. 58-62118.

【0003】ハリタケ科のキノコであるヤマブシタケに
ついても、該ヤマブシタケの子実体中にはオクタデセン
酸誘導体、イソインドリノン誘導体、フタリド誘導体が
含まれており、これらには子宮頸癌細胞に対する殺細胞
効果のあることが特開平3−157347、特開平3−
157367、特開平3−157379に報告されてい
る。
[0003] As for the mushrooms belonging to the mushrooms, Ganoderma lucidum, octadecenoic acid derivatives, isoindolinone derivatives and phthalide derivatives are contained in the fruiting bodies of the mushrooms, which have a cytocidal effect on cervical cancer cells. There are some cases in JP-A-3-157347 and JP-A-3-157347.
157367 and JP-A-3-157379.

【0004】[0004]

【発明が解決しようとする課題】しかし、ヤマブシタケ
の培養菌糸体中に含まれる化合物及びその薬剤効果につ
いては全く報告がない。
However, there are no reports on the compounds contained in the cultured mycelium of Pleurotus cornucopiae and their drug effects.

【0005】[0005]

【課題を解決するための手段】しかして本発明者らは、
叙上の如き実情に鑑み、ヤマブシタケの培養菌糸体中に
含まれる化合物及びその薬剤効果について鋭意研究した
結果、ヤマブシタケの培養菌糸体中には特定の化学構造
からなる新規のシアタン( cyathane )誘導体が含まれ
ており、該シアタン( cyathane )誘導体には神経成長
因子(NGF)産生誘導効果及び抗菌効果のあることを
見出した。
However, the present inventors have
In light of the above-mentioned circumstances, as a result of diligent research on compounds contained in cultured mycelium of Yamabushitake and its drug effect, a new cyathane derivative having a specific chemical structure was found in the cultured mycelium of Yamabushitake. It was found that the cyathane derivative contained therein has a nerve growth factor (NGF) production inducing effect and an antibacterial effect.

【0006】すなわち本発明は、下記の式1で示される
シアタン( cyathane )誘導体及び該シアタン( cyath
ane )誘導体を有効成分とする神経成長因子(NGF)
産生誘導剤並びに抗菌剤に係る。
That is, the present invention provides a cyathane derivative represented by the following formula 1 and the cyathane derivative.
nerve growth factor (NGF) containing ane) derivative as an active ingredient
It relates to production inducers and antibacterial agents.

【0007】[0007]

【式1】 [Formula 1]

【0008】式1で示されるシアタン( cyathane )誘
導体はヤマブシタケの菌糸体を次のように処理すること
によって得られる。先ず、ヤマブシタケの菌糸体をSG
C培地(グルコース、スターチ、コーンスティープリカ
ー、KH2PO4、CuSO4、ZnCl2、塩酸チアミン
及び水系のPH=5.3〜5.5に調製された液体培
地)にて30℃で4週間培養する。得られた培養菌糸体
を遠心分離によって上澄液と沈殿物である培養菌糸体と
に分離し、該培養菌糸体を水及び有機溶媒の均一系で抽
出する。この場合、水及び有機溶媒の均一系としては、
80〜85%メタノールやエタノール、85%アセトン
等がある。抽出は通常室温で行なうが、加熱還流しても
よく、抽出時間は通常1〜72時間である。例えば、8
5%エタノール中にヤマブシタケの培養菌糸体を加え、
ホモジナイズ処理し、これを室温で一昼夜放置した後、
濾過して抽出液を得、該抽出液を減圧下に40〜45℃
で加熱して有機溶媒を蒸発することにより水相を得るの
である。
The cyathane derivative represented by the formula 1 can be obtained by treating the mycelium of Pleurotus cornucopiae as follows. First, the mycelium of Yamabushitake is SG
C medium (a liquid medium prepared by adjusting glucose, starch, corn steep liquor, KH 2 PO 4 , CuSO 4 , ZnCl 2 , thiamine hydrochloride and aqueous PH = 5.3 to 5.5) at 30 ° C. for 4 weeks Incubate. The obtained cultured mycelium is separated into a supernatant and a cultured mycelium that is a precipitate by centrifugation, and the cultured mycelium is extracted with a homogeneous system of water and an organic solvent. In this case, as a homogeneous system of water and organic solvent,
80-85% methanol, ethanol, 85% acetone and the like. The extraction is usually performed at room temperature, but may be heated under reflux, and the extraction time is usually 1 to 72 hours. For example, 8
Add the mycelium of Yamabushitake culture to 5% ethanol,
After homogenizing and letting this stand at room temperature for a whole day and night,
The extract is obtained by filtration, and the extract is under reduced pressure at 40 to 45 ° C.
The aqueous phase is obtained by heating at to evaporate the organic solvent.

【0009】次に、該水相を水及び有機溶媒の混合系で
液−液分配抽出処理して有機溶媒層を分取し、該有機溶
媒層から有機溶媒を蒸発して乾固物を得る。この場合、
有機溶媒としては、クロロホルム、酢酸エチル、ジエチ
ルエーテル等がある。例えば、上記水相に酢酸エチルを
加え、振盪後、放置して分層した酢酸エチル層を分取
し、該酢酸エチル層を減圧下に40〜45℃で加熱して
酢酸エチルを蒸発することにより乾固物を得るのであ
る。
Next, the aqueous phase is subjected to a liquid-liquid partition extraction process with a mixed system of water and an organic solvent to separate an organic solvent layer, and the organic solvent is evaporated from the organic solvent layer to obtain a dry matter. . in this case,
Examples of the organic solvent include chloroform, ethyl acetate, diethyl ether and the like. For example, ethyl acetate is added to the above aqueous phase, after shaking, the ethyl acetate layer separated by standing is separated, and the ethyl acetate layer is heated under reduced pressure at 40 to 45 ° C. to evaporate the ethyl acetate. To obtain a dry solid.

【0010】上記乾固物はそれ自体が神経成長因子(N
GF)産生誘導剤及び抗菌剤として有効なものである
が、該乾固物から不純物を除去してその神経成長因子
(NGF)産生誘導効果及び抗菌効果を高めるために、
該乾固物をクロマト分画処理するのが好ましく、クロマ
ト分画処理したものを更に再分画処理して目的とするシ
アタン( cyathane )誘導体を単離するのがより好まし
い。この場合、詳しくは実施例で後述するように、クロ
ロホルム/アセトン、ヘキサン/エーテル等を展開溶媒
とするシリカゲルカラムクロマトグラフィー或は薄層ク
ロマトグラフィーを用いてクロマト分画処理することが
でき、またODSカラムを用いた高速液体クロマトグラ
フィーで再分画処理することができる。
The dry matter itself is a nerve growth factor (N
It is effective as a GF) production inducer and an antibacterial agent, but in order to remove impurities from the dried solid matter to enhance its nerve growth factor (NGF) production inducing effect and antibacterial effect,
It is preferable to subject the dried solid matter to a chromatographic fractionation, and it is more preferable to further subject the chromatographically fractionated product to a re-fractionation treatment to isolate the desired cyathane derivative. In this case, as will be described later in detail in the Examples, it can be subjected to chromatographic fractionation using silica gel column chromatography or thin layer chromatography using chloroform / acetone, hexane / ether, etc. as a developing solvent, and ODS. Re-fractionation can be performed by high performance liquid chromatography using a column.

【0011】かくして再分画処理することにより単離さ
れる化合物の物理化学的性質及び構造解析結果は下記の
通りである。 (1)分子量:434(C25386) (2)赤外線吸収スペクトル:3380,2960,2
870,1376,1170,1062,1041,1
010cm-1 (3)核磁気共鳴スペクトル(1H−NMR,δ):0.
96(3H,d,J=6.60),0.97(3H,
d,J=6.60),1.00(3H,s),1.02
(3H,s),1.50(2H,m),1.52(1
H,m),1.63(1H,m),1.66(2H,
m),2.27(2H,m),2.32(1H,m),
2.41(1H,m),2.48(1H,m),2.7
5(1H,heptet,J=6.60),3.31(1H,
dd,J=10.56,10.88),3.41(1
H,dd,J=8.58,8.91),3.56(1
H,dd,J=8.91,8.58),3.63(1
H,m),3.89(1H,d,J=9.74),3.
99(1H,dd,J=10.56,5.40),4.
00(1H,d,J=11.88),4.31(1H,
d,J=11.88),4.58(1H,d,J=8.
58),4.81(1H,br.d,J=9.74),
6.01(1H,br.d,J=7.26) (4)核磁気共鳴スペクトル(13C−NMR,δ):1
6.5,21.4,21.9,24.5,26.9,2
7.8,28.3,28.4,36.5,38.1,4
1.5,42.6,49.4,66.0,66.9,6
9.9,71.3,73.3,74.7,79.8,9
8.7,135.7,136.8,139.5,13
9.8 (5)溶媒に対する溶解性:クロロホルム、アセトン、
酢酸エチル、メタノールに可溶、エタノールにやや可
溶、水に不溶 (6)塩基性、中性、酸性の区別:中性物質 (7)色及び性状:無色油状
The physicochemical properties and the results of structural analysis of the compound thus isolated by the re-fractionation treatment are as follows. (1) Molecular weight: 434 (C 25 H 38 O 6 ) (2) Infrared absorption spectrum: 3380, 2960, 2
870, 1376, 1170, 1062, 1041, 1
010 cm -1 (3) Nuclear magnetic resonance spectrum ( 1 H-NMR, δ): 0.
96 (3H, d, J = 6.60), 0.97 (3H,
d, J = 6.60), 1.00 (3H, s), 1.02
(3H, s), 1.50 (2H, m), 1.52 (1
H, m), 1.63 (1H, m), 1.66 (2H,
m), 2.27 (2H, m), 2.32 (1H, m),
2.41 (1H, m), 2.48 (1H, m), 2.7
5 (1H, heptet, J = 6.60), 3.31 (1H,
dd, J = 10.56, 10.88), 3.41 (1
H, dd, J = 8.58, 8.91), 3.56 (1
H, dd, J = 8.91, 8.58), 3.63 (1
H, m), 3.89 (1H, d, J = 9.74), 3.
99 (1H, dd, J = 10.56, 5.40), 4.
00 (1H, d, J = 11.88), 4.31 (1H,
d, J = 11.88), 4.58 (1H, d, J = 8.
58), 4.81 (1H, br.d, J = 9.74),
6.01 (1H, br.d, J = 7.26) (4) Nuclear magnetic resonance spectrum ( 13 C-NMR, δ): 1
6.5, 21.4, 21.9, 24.5, 26.9, 2
7.8, 28.3, 28.4, 36.5, 38.1, 4
1.5, 42.6, 49.4, 66.0, 66.9, 6
9.9, 71.3, 73.3, 74.7, 79.8, 9
8.7, 135.7, 136.8, 139.5, 13
9.8 (5) Solubility in solvent: chloroform, acetone,
Ethyl acetate, soluble in methanol, slightly soluble in ethanol, insoluble in water (6) Distinction between basic, neutral, and acidic: neutral substance (7) Color and properties: colorless oil

【0012】上記の物理化学的性質及び構造解析結果か
ら、単離される化合物は式1で示されるシアタン( cya
thane )誘導体であることが決定された。
From the above physicochemical properties and the results of structural analysis, the isolated compound is represented by the formula 1
thane) was determined to be a derivative.

【0013】詳しくは実施例で後述するように、本発明
のシアタン( cyathane )誘導体は神経成長因子(NG
F)産生誘導効果及び抗菌効果があり、神経成長因子
(NGF)産生誘導効果を有する化合物は老人性痴呆症
治療剤としての利用が注目されており、また抗菌効果を
有する化合物は天然抗菌剤として食品への利用が注目さ
れている。
As will be described later in detail in Examples, the cyathane derivative of the present invention is a nerve growth factor (NG).
F) A compound having a production-inducing effect and an antibacterial effect and having a nerve growth factor (NGF) production-inducing effect has been attracting attention as a therapeutic agent for senile dementia, and a compound having an antibacterial effect is used as a natural antibacterial agent. Attention has been paid to its use for food.

【0014】[0014]

【実施例】【Example】

シアタン( cyathane )誘導体の抽出及び単離 ヤマブシタケの菌糸体をSGC培地(前掲のもの)にて
4週間培養し、培養菌糸体を得た。85%エタノール5
リットルに該培養菌糸体700g(湿重量)を加え、ホ
モジナイズ処理し、これを室温で一昼夜放置した後、濾
過して抽出液を得た。残渣に85%エタノール5リット
ルを加え、同様に抽出処理を行なって抽出液を得、これ
を1回目の抽出液と合わせた。そして合わせた抽出液を
減圧下に40〜45℃で加熱してエタノールを蒸発する
ことにより水相を得た。
Extraction and isolation of cyathane derivative The mycelium of Pleurotus cornucopiae was cultured in SGC medium (previously described) for 4 weeks to obtain a cultured mycelium. 85% ethanol 5
700 g (wet weight) of the cultured mycelium was added to 1 liter, homogenized, allowed to stand at room temperature for 24 hours, and then filtered to obtain an extract. To the residue was added 5 liters of 85% ethanol and the same extraction treatment was performed to obtain an extract, which was combined with the first extract. Then, the combined extracts were heated at 40 to 45 ° C. under reduced pressure to evaporate ethanol to obtain an aqueous phase.

【0015】上記水相に酢酸エチル1リットルを加え、
振盪後、放置して分層した酢酸エチル層を分取した。残
渣に酢酸エチル1リットルを加え、同様に液−液分配抽
出処理を行なって酢酸エチル層を分取した。同様の操作
を3回繰り返し、分取した酢酸エチル層を1回目の酢酸
エチル層と合わせた。合わせた酢酸エチル層を減圧下に
40〜45℃で加熱して酢酸エチルを蒸発し、更にデシ
ケータで乾燥して乾固物7.0gを得た。
1 liter of ethyl acetate was added to the above aqueous phase,
After shaking, the mixture was allowed to stand and the separated ethyl acetate layer was separated. Ethyl acetate (1 liter) was added to the residue, and liquid-liquid partition extraction treatment was performed in the same manner to separate the ethyl acetate layer. The same operation was repeated 3 times, and the separated ethyl acetate layer was combined with the first ethyl acetate layer. The combined ethyl acetate layers were heated under reduced pressure at 40 to 45 ° C. to evaporate ethyl acetate, and then dried with a desiccator to obtain 7.0 g of a dry solid.

【0016】上記乾固物をヘキサンで溶解し、ワコーゲ
ルC−200(和光純薬社製)を用いてカラムクロマト
グラフィーを行なった。この際、展開溶媒として、順次
極性が大きくなるように、クロロホルム/アセトン=
9:1、8:2、7:3、1:1を各200ml用い、5
0mlの画分を合計16画分得た。このうちのクロロホル
ム/アセトン=1:1溶出画分を更にシリカゲルカラム
クロマトグラフィーに供し、展開溶媒としてクロロホル
ム/メタノール=9:1を80ml用い、10mlの画分を
合計8画分得た。このうちの第2画分から式1に示され
るシアタン( cyathane )誘導体を44.6mg単離し
た。
The dried product was dissolved in hexane and subjected to column chromatography using Wakogel C-200 (manufactured by Wako Pure Chemical Industries, Ltd.). At this time, as a developing solvent, chloroform / acetone =
Use 9: 1, 8: 2, 7: 3, 1: 1 for each 200 ml, 5
A total of 16 fractions of 0 ml were obtained. The chloroform / acetone = 1: 1 elution fraction was further subjected to silica gel column chromatography, and 80 ml of chloroform / methanol = 9: 1 was used as a developing solvent to obtain a total of 8 fractions of 10 ml. From the second fraction, 44.6 mg of the cyathane derivative represented by the formula 1 was isolated.

【0017】シアタン( cyathane )誘導体の神経成長
因子(NGF)産生誘導効果 古川らの方法{バイオケミカル アンド バイオフィジ
カル リサーチ コミュニケーションズ( Biochemical
and Biophysical Research Communications),13
6,57−63(1986)}にしたがい、胎生後期
(19日令)ラット皮質初代アストログリア細胞を培養
器に10%牛胎仔血清を含むダルベッコ変法イーグル培
地(DMEM)で培養(1〜2週間、3日毎に培地を交
換)し、コンフルエントに達したところで、0.5%牛
血清アルブミンを含むDMEMに変えて数日培養した。
ここへジメチルスルホキシド(DMSO)に溶解したシ
アタン( cyathane )誘導体を所定濃度になるように
0.5%牛血清アルブミンを含むDMEMにて調製し、
投与した。24時間の培養後、培養液を集め、古川らの
方法{ジャーナル オブ ニューロケミストリー( Jou
rnal of Neurochemistry),40,734−744(1
983)}によるエンザイムアッセイ法で神経成長因子
(NGF)濃度を測定した。シアタン( cyathane )誘
導体を投与しないで培養した対照群とシアタン( cyath
ane )誘導体を1mM投与して培養した群との間でt検
定を行なった。その結果、投与した群は1%の危険率で
有効と有意検定された。
Nerve growth factor (NGF) production-inducing effect of cyathane derivatives Furukawa et al.'S method {Biochemical and Biophysical Research Communications
and Biophysical Research Communications), 13
6, 57-63 (1986)}, and cultured in early incubator (19-day-old) rat cortical astroglial cells in a Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum (1-2 The medium was replaced every 3 days for a week), and when confluent was reached, the medium was changed to DMEM containing 0.5% bovine serum albumin and cultured for several days.
Here, a cyathane derivative dissolved in dimethyl sulfoxide (DMSO) was prepared with DMEM containing 0.5% bovine serum albumin to a predetermined concentration,
Was administered. After culturing for 24 hours, the culture solution was collected and the method of Furukawa et al. {Journal of Neurochemistry (Jou
rnal of Neurochemistry), 40, 734-744 (1
983)}, the nerve growth factor (NGF) concentration was measured by the enzyme assay method. Control group and cyathane (cyathane) cultured without administration of cyathane derivative
An ane) derivative was administered at 1 mM, and a t-test was carried out with a group cultured. As a result, the administered group was significantly tested as effective at a risk rate of 1%.

【0018】シアタン( cyathane )誘導体の抗菌効果 肉エキス1.0%、ポリペプトン0.5%、塩化ナトリ
ウム0.25%、寒天1.5%を含むPH7.2〜7.
4の普通寒天培地を作製し、試験管に15ml及び6mlず
つを分注し、オートクレーブ(121℃で20分)にて
加圧蒸気滅菌を行なった。滅菌済みのシャーレに加圧蒸
気滅菌した15mlの培地を無菌的に流入し、平面に固定
させ基層とした。別に加圧蒸気滅菌した6mlの培地を溶
解し、55〜60℃まで冷却したものに、5mlの液体培
地中で30℃で16時間振盪培養した枯草菌(バチルス
ズブチリス)を50μl接種し、よく混合した後、こ
れを菌層として上記基層の上に流入し、検定用培地とし
た。該検定用培地の上に、シアタン( cyathane )誘導
体の10mg/ml溶液を染み込ませて溶媒を乾かしたペー
パーディスクを静かにピンセットで乗せ、30℃の恒温
室で24時間培養後、生成した阻止円の直径を測定し、
下記の式2により抗菌活性を求めた。
Antibacterial effect of cyathane derivative PH7.2 containing meat extract 1.0%, polypeptone 0.5%, sodium chloride 0.25%, agar 1.5%.
4 ordinary agar medium was prepared, 15 ml and 6 ml of each were dispensed into a test tube, and autoclaved (20 minutes at 121 ° C.) to perform autoclave sterilization. 15 ml of a medium subjected to pressure steam sterilization was aseptically flown into a sterilized petri dish and fixed on a flat surface to form a base layer. Separately, 6 ml of medium sterilized by autoclaving was dissolved, cooled to 55-60 ° C, and inoculated with 50 μl of Bacillus subtilis cultivated in 5 ml of liquid medium at 30 ° C for 16 hours with shaking, and mixed well. After that, this was used as a fungal layer and flowed onto the above-mentioned base layer to obtain an assay medium. On the assay medium, a 10 mg / ml solution of a cyathane derivative was soaked in a solution and a paper disk dried with a solvent was gently placed with tweezers, and incubated for 24 hours in a thermostatic chamber at 30 ° C. The diameter of
The antibacterial activity was determined by the following formula 2.

【式2】抗菌活性(mm)=測定した阻止円の直径(mm)
−ペーパーディスクの直径(8mm) 抗菌活性は3mmであり、シアタン( cyathane )誘導体
はバチルス ズブチリスに対して抗菌効果のあることが
検定された。
[Formula 2] Antibacterial activity (mm) = measured diameter of blocking circle (mm)
-Diameter of paper disc (8 mm) antibacterial activity is 3 mm, cyathane derivative was assayed to have antibacterial effect against Bacillus subtilis.

【0019】[0019]

【発明の効果】既に明らかなように、以上説明した本発
明のシアタン( cyathane )誘導体には神経成長因子
(NGF)産生誘導剤及び抗菌剤として有効という効果
がある。
As is apparent, the cyathane derivative of the present invention described above is effective as a nerve growth factor (NGF) production inducer and an antibacterial agent.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 坂本 秀樹 栃木県那須郡西那須野町大字井口47番地12 (72)発明者 石黒 幸雄 栃木県那須郡西那須野町東三島5丁目96番 地19 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Hideki Sakamoto 47 Izaguchi, Nishinasuno-cho, Nasu-gun, Tochigi 12 12 (72) Yukio Ishiguro 5-96 Higashimishima, Nishinasuno-cho, Nasu-gun, Tochigi 19

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 下記の式1で示されるシアタン( cyath
ane )誘導体。 【式1】
1. A cyanate represented by the following formula 1 (cyath
ane) derivatives. [Formula 1]
【請求項2】 請求項1記載のシアタン( cyathane )
誘導体を有効成分とする神経成長因子(NGF)産生誘
導剤。
2. The cyathane according to claim 1.
A nerve growth factor (NGF) production inducer containing a derivative as an active ingredient.
【請求項3】 請求項1記載のシアタン( cyathane )
誘導体を有効成分とする抗菌剤。
3. The cyathane according to claim 1.
An antibacterial agent containing a derivative as an active ingredient.
JP5240544A 1993-03-04 1993-08-31 Sheatan derivative, nerve growth factor production inducer containing the same as active ingredient, and antibacterial agent Expired - Fee Related JP2657894B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP5240544A JP2657894B2 (en) 1993-08-31 1993-08-31 Sheatan derivative, nerve growth factor production inducer containing the same as active ingredient, and antibacterial agent
US08/196,049 US5391544A (en) 1993-03-04 1994-02-10 Cyathane derivatives and antimicrobial agents containing same
DE69403242T DE69403242T2 (en) 1993-03-04 1994-03-03 Cyathane derivatives and nerve growth factor containing them produce stimulators and antimicrobial agents
AT94301549T ATE153340T1 (en) 1993-03-04 1994-03-03 CYATHANE DERIVATIVES AND THESE CONTAINING NERVE GROWTH FACTOR PRODUCTION STIMULATORS AND ANTIMICROBIAL AGENTS
ES94301549T ES2104272T3 (en) 1993-03-04 1994-03-03 DERIVATIVES OF CIATANO AND STIMULATORS OF THE PRODUCTION OF NERVOUS GROWTH FACTOR AND ANTIMICROBIAL AGENTS THAT CONTAIN THEM.
EP94301549A EP0613903B1 (en) 1993-03-04 1994-03-03 Cyathane derivatives and production stimulators of nerve growth factors and antimicrobial agents containing same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5240544A JP2657894B2 (en) 1993-08-31 1993-08-31 Sheatan derivative, nerve growth factor production inducer containing the same as active ingredient, and antibacterial agent
US08/196,049 US5391544A (en) 1993-03-04 1994-02-10 Cyathane derivatives and antimicrobial agents containing same

Publications (2)

Publication Number Publication Date
JPH0770133A true JPH0770133A (en) 1995-03-14
JP2657894B2 JP2657894B2 (en) 1997-09-30

Family

ID=26534772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5240544A Expired - Fee Related JP2657894B2 (en) 1993-03-04 1993-08-31 Sheatan derivative, nerve growth factor production inducer containing the same as active ingredient, and antibacterial agent

Country Status (1)

Country Link
JP (1) JP2657894B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005239669A (en) * 2004-02-27 2005-09-08 Yukito Akiyama Cyathane derivative and antibacterial agent containing the derivative as active component
JP2005272346A (en) * 2004-03-24 2005-10-06 Otsuka Bebareji Kk New compound contained in hericium erinaceum and anti-methicillin-resistant staphylococcus aureus agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005239669A (en) * 2004-02-27 2005-09-08 Yukito Akiyama Cyathane derivative and antibacterial agent containing the derivative as active component
JP2005272346A (en) * 2004-03-24 2005-10-06 Otsuka Bebareji Kk New compound contained in hericium erinaceum and anti-methicillin-resistant staphylococcus aureus agent

Also Published As

Publication number Publication date
JP2657894B2 (en) 1997-09-30

Similar Documents

Publication Publication Date Title
US3983140A (en) Physiologically active substances
Cole et al. Tremorgenic toxin from Penicillium verruculosum
CN107556362B (en) Extraction method of cucurbitane type triterpenoid and medical application of cucurbitane type triterpenoid in resisting Alzheimer disease
JPH0769961A (en) Cyathane derivative, and neuro growth factor production inducing agent and antimicrobial agent using the same as active component
JP2632121B2 (en) Sheatan derivative, nerve growth factor production inducer containing the same as active ingredient, and antibacterial agent
CN116730919B (en) A diterpene alkaloid compound and its extraction method and application
US5391544A (en) Cyathane derivatives and antimicrobial agents containing same
KR0176413B1 (en) Deckerin as an anticancer agent
JPH0770168A (en) Cyathane derivative and nerve growth factor production inducer containing the same and antimicrobial agent
JPH0770133A (en) Cyathane derivative and nerve growth factor production inducing agent and antigbacterial agent containing the derivative as active component
JP2657883B2 (en) Sheatan derivative, nerve growth factor production inducer containing the same as active ingredient, and antibacterial agent
JP4095153B2 (en) Siatan derivative and nerve growth factor production inducer comprising the same as an active ingredient
CN108314618B (en) Sesquiterpenoids and their extraction methods and their medicinal uses against Alzheimer's disease
CN111671780A (en) Preparation method and application of transosseous lignans with neuroprotective activity
US5565436A (en) Production stimulators of nerve growth factors comprising cyathane derivatives
JPH09124541A (en) New compound and nerve growth factor productive inducer with the same as active ingredient
JPH0826010B2 (en) Chroman derivative, PGE2 production inhibitor and NGF production inducer containing the same as active ingredient
JPH09241291A (en) Cyathane derivative and nerve growth factor production inducer comprising the same as active ingredient
JP2792010B2 (en) Phthalide derivative and cell killer for cervical cancer cells containing the same as active ingredient
JPH0772157B2 (en) Benzyl alcohol derivative, PGE2 production inhibitor and NGF production inducer containing the same as active ingredient
JP2734136B2 (en) Octadecenoic acid derivative and cell killer for cervical cancer cells containing the same as active ingredient
Ueno Citreoviridin
US20110092585A1 (en) Immunomodulatory pharmaceutical composition and a process for preparation thereof
JP2757342B2 (en) Isoindolinone derivative, cervical cancer cell killing agent containing the same as active ingredient, and method for producing the same
KR100449245B1 (en) Composition containing liriope platyphylla having teatment effect for nervous diseases

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080606

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090606

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100606

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100606

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110606

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120606

Year of fee payment: 15

LAPS Cancellation because of no payment of annual fees